维布妥昔单抗联合AVD一线治疗早期不良预后霍奇金淋巴瘤(BREACH):一项多中心、开放标签、随机、II期试验
BREACH研究纳入170例18-60岁、具有至少1项不良EORTC/LYSA标准的初治早期不良霍奇金淋巴瘤患者,按2:1随机接受4周期BV-AVD或ABVD后行30 Gy受累淋巴结放疗。主要终点为2周期后PET阴性率,BV-AVD组为82.3%,ABVD组为75.4%,研究达到主要终点;2年PFS分别为97.3%和92.6%。
要点
- 2周期后PET阴性率BV-AVD组82.3%(90% CI 75.3-88.0),ABVD组75.4%(90% CI 64.3-84.5)。
- 2年PFS BV-AVD组97.3%(95% CI 91.9-99.1),ABVD组92.6%(95% CI 81.4-97.2)。
- 高总代谢肿瘤体积与显著缩短的PFS相关(HR 17.9,95% CI 2.2-145.5,P<.001)。
核心结论
- BV-AVD较ABVD在2周期后PET阴性率上显示出改善。
研究设计与样本
- BREACH为多中心、随机、开放标签、II期试验(ClinicalTrials.gov NCT02292979)。
- 纳入18-60岁、具有至少1项不良EORTC/LYSA标准的初治早期不良霍奇金淋巴瘤患者。
- 患者按2:1随机接受4周期BV-AVD或ABVD,后续行30 Gy受累淋巴结放疗。
- 主要终点为2周期后经专家独立审查按Deauville评分判定的PET缓解率;研究设计检验BV-AVD组2周期后PET阴性率是否优于75%。
- 2015年3月至2016年10月共入组170例患者。
主要发现
- 2周期后BV-AVD组113例中93例(82.3%;90% CI 75.3-88.0)PET阴性(Deauville评分1-3),ABVD组57例中43例(75.4%;90% CI 64.3%-84.5%)PET阴性。
- 2年PFS在BV-AVD组为97.3%(95% CI 91.9-99.1),ABVD组为92.6%(95% CI 81.4%-97.2%)。
- 高总代谢肿瘤体积与显著缩短的PFS相关(HR 17.9;95% CI 2.2-145.5;P<.001)。
- 高总代谢肿瘤体积患者中,2年PFS率在BV-AVD组为90.9%(95% CI 74.4-97.0),ABVD组为70.7%(95% CI 39.4%-87.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979). METHODS: BREACH is a multicenter, randomized, open-label, phase II trial. Eligible patients were age 18-60 years with ≥ 1 unfavorable EORTC/LYSA criterion. Patients were randomly assigned (2:1) to four cycles of BV-AVD or standard doxorubicin, bleomycin, vincristine, and dacarbazine (ABVD), followed by 30 Gy involved node radiotherapy. The primary end point was the positron emission tomography (PET) response rate after two cycles by expert independent review using the Deauville score. The study was designed to test if the PET-negative rate after two cycles of BV-AVD was superior to 75%. We hypothesized a 10% increase in the PET-negative rate after two cycles of BV-AVD. RESULTS: Between March 2015 and October 2016, 170 patients were enrolled. After two cycles, the primary end point of the study was met: 93 (82.3%; 90% CI, 75.3 to 88.0) of 113 patients in the BV-AVD arm were PET-negative (Deauville score 1-3) compared with 43 (75.4%; 90% CI, 64.3% to 84.5%) of 57 in the ABVD arm. The 2-year progression-free survival (PFS) was 97.3% (95% CI, 91.9 to 99.1) and 92.6% (95% CI, 81.4% to 97.2%) in the BV-AVD and ABVD arms, respectively. High total metabolic tumor volume was associated with a significantly shorter PFS (hazard ratio, 17.9; 95% CI, 2.2 to 145.5; P < .001). For patients with high total metabolic tumor volume, the 2-year PFS rate was 90.9% (95% CI, 74.4 to 97.0) and 70.7% (95% CI, 39.4% to 87.9%) in the BV-AVD and ABVD arms, respectively. CONCLUSION: BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.
引用
- Fornecker LM, Lazarovici J, Aurer I, et al. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. J Clin Oncol. 2022. PMID: 35867960. doi:10.1200/JCO.21.01281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。